[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580655":3},{"organization":4,"outcomesModule":7,"designInfo":61,"detailedDescription":11,"studyPopulation":11,"armGroups":68,"interventions":92,"overallOfficials":11,"centralContacts":113,"locations":123,"responsibleParty":242,"collaborators":11,"id":244,"slug":11,"hasResults":245,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":11,"eligibilityCriteria":249,"healthyVolunteers":245,"sex":250,"minAge":251,"maxAge":11,"enrollmentInfo":252,"targetDuration":11,"studyType":255,"phases":256,"briefSummary":259,"conditions":260,"keywords":11,"overallStatus":140,"whyStopped":11,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},{"fullName":5,"class":6},"Immunocore Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":27,"otherOutcomes":11},[9,13,15,17,19,21,23,25],{"measure":10,"description":11,"timeFrame":12},"Dose Escalation: Percentage of participants with ≥1 dose-limiting toxicity (DLT)",null,"Up to ~24 months",{"measure":14,"description":11,"timeFrame":12},"Dose Escalation: Percentage of participants with ≥1 adverse event (AE)",{"measure":16,"description":11,"timeFrame":12},"Dose Escalation: Percentage of participants with ≥1 serious adverse event (SAE)",{"measure":18,"description":11,"timeFrame":12},"Dose Escalation: Percentage of participants with significant changes in electrocardiogram (ECG) recordings",{"measure":20,"description":11,"timeFrame":12},"Dose Escalation: Percentage of participants with significant changes in vital signs",{"measure":22,"description":11,"timeFrame":12},"Dose Escalation: Percentage of participants with significant changes in laboratory results",{"measure":24,"description":11,"timeFrame":12},"Dose Escalation: Percentage of participants with a dose interruption, reduction, or discontinuation",{"measure":26,"description":11,"timeFrame":12},"Expansion: Best Overall Response (BOR) as Determined by RECIST v1.1",[28,31,33,35,37,39,41,43,45,47,49,51,53,55,57,59],{"measure":29,"description":11,"timeFrame":30},"Dose Escalation: Best Overall Response (BOR) as Determined by RECIST v1.1 with IMC-R117C Monotherapy and in Combination","Up to ~36 months",{"measure":32,"description":11,"timeFrame":30},"Dose Escalation: Duration of Response (DOR) as Determined by RECIST v1.1 with IMC-R117C Monotherapy and in Combination",{"measure":34,"description":11,"timeFrame":30},"Dose Escalation: Progression-free survival (PFS) as Determined by RECIST v1.1 with IMC-R117C Monotherapy and in Combination",{"measure":36,"description":11,"timeFrame":30},"Dose Escalation: Overall Survival (OS) with IMC-R117C Monotherapy and in Combination",{"measure":38,"description":11,"timeFrame":30},"Expansion: Duration of Response (DOR) as Determined by RECIST v1.1 with IMC-R117C Monotherapy",{"measure":40,"description":11,"timeFrame":30},"Expansion: Progression-free survival (PFS) as Determined by RECIST v1.1 with IMC-R117C Monotherapy",{"measure":42,"description":11,"timeFrame":30},"Expansion: Overall Survival (OS) with IMC-R117C Monotherapy",{"measure":44,"description":11,"timeFrame":12},"Expansion: Percentage of participants with ≥1 Adverse Events (AE)",{"measure":46,"description":11,"timeFrame":12},"Expansion: Percentage of participants with ≥1 Serious Adverse Events (SAE)",{"measure":48,"description":11,"timeFrame":12},"Expansion: Percentage of participants with significant changes in electrocardiogram (ECG) recordings",{"measure":50,"description":11,"timeFrame":12},"Expansion: Percentage of participants with significant changes in vital signs",{"measure":52,"description":11,"timeFrame":12},"Expansion: Percentage of participants with significant changes in laboratory findings",{"measure":54,"description":11,"timeFrame":12},"Expansion: Percentage of participants with dose interruptions, reductions, or discontinuation",{"measure":56,"description":11,"timeFrame":30},"All Study: Plasma Concentration of IMC-R117C",{"measure":58,"description":11,"timeFrame":30},"All Study: Incidence of anti-IMC-R117C Antibody Formation",{"measure":60,"description":11,"timeFrame":30},"All Study: Incidence of tumor expression and localization of PIWIL1",{"allocation":62,"interventionModel":63,"interventionModelDescription":64,"primaryPurpose":65,"observationalModel":11,"timePerspective":11,"maskingInfo":66},"NON_RANDOMIZED","SEQUENTIAL","The study will include sequential assignment for non-randomized and randomized arms.","TREATMENT",{"masking":67,"maskingDescription":11,"whoMasked":11},"NONE",[69,75,81,87],{"label":70,"type":71,"description":72,"interventionNames":73},"Arm A: IMC-R117C Monotherapy Dose-Escalation","EXPERIMENTAL","Participants receive IMC-R117C intravenous (IV) infusion.",[74],"Drug: IMC-R117C",{"label":76,"type":71,"description":77,"interventionNames":78},"Arm B: IMC-R117C Combination Dose-Escalation","Participants receive IMC-R117C IV infusion in combination with standard of care chemotherapy and antiangiogenic agent",[74,79,80],"Drug: Chemotherapy drug","Drug: Antiangiogenic Agent",{"label":82,"type":71,"description":83,"interventionNames":84},"Arm C: IMC-R117C Combination Dose-Escalation","Participants receive IMC-R117C IV infusion with targeted therapies",[74,85,86],"Drug: Kinase inhibitor","Drug: Monoclonal antibody",{"label":88,"type":89,"description":90,"interventionNames":91},"Arm D: Control Arm","ACTIVE_COMPARATOR","Participants receive standard of care chemotherapy and antiangiogenic agent",[79,80],[93,98,101,104,107,110],{"type":94,"name":95,"description":96,"armGroupLabels":97,"otherNames":11},"DRUG","IMC-R117C","IV infusion",[70,76,82],{"type":94,"name":99,"description":96,"armGroupLabels":100,"otherNames":11},"Chemotherapy drug",[76,88],{"type":94,"name":99,"description":102,"armGroupLabels":103,"otherNames":11},"oral",[76],{"type":94,"name":105,"description":102,"armGroupLabels":106,"otherNames":11},"Kinase inhibitor",[82],{"type":94,"name":108,"description":96,"armGroupLabels":109,"otherNames":11},"Antiangiogenic Agent",[76,88],{"type":94,"name":111,"description":96,"armGroupLabels":112,"otherNames":11},"Monoclonal antibody",[82],[114,119],{"name":115,"role":116,"phone":117,"phoneExt":11,"email":118},"Immunocore Medical Information","CONTACT","844-466-8661","medical.information@immunocore.com",{"name":120,"role":116,"phone":121,"phoneExt":11,"email":122},"Immunocore Medical Information EU","+00 800-744-51111","medinfo.eu@immunocore.com",[124,138,147,158,166,175,185,195,204,214,224,229,237],{"facility":125,"status":126,"city":127,"state":128,"zip":129,"country":130,"countryCode":131,"cosmosGeoPoint":132,"geoPoint":137,"contacts":11},"St Vincent's Hospital","ACTIVE_NOT_RECRUITING","Darlinghurst","Sydney","NSW 2010","Australia","AU",{"type":133,"coordinates":134},"Point",[135,136],151.21925,-33.87939,{"lat":136,"lon":135},{"facility":139,"status":140,"city":141,"state":11,"zip":11,"country":130,"countryCode":131,"cosmosGeoPoint":142,"geoPoint":146,"contacts":11},"Peter MacCallum Cancer Centre","RECRUITING","Melbourne",{"type":133,"coordinates":143},[144,145],144.96332,-37.814,{"lat":145,"lon":144},{"facility":148,"status":140,"city":149,"state":11,"zip":150,"country":151,"countryCode":152,"cosmosGeoPoint":153,"geoPoint":157,"contacts":11},"Institut Jules Bordet","Anderlecht","1070","Belgium","BE",{"type":133,"coordinates":154},[155,156],4.31454,50.83619,{"lat":156,"lon":155},{"facility":159,"status":140,"city":160,"state":11,"zip":11,"country":151,"countryCode":152,"cosmosGeoPoint":161,"geoPoint":165,"contacts":11},"Universitair Ziekenhuis Gent","Ghent",{"type":133,"coordinates":162},[163,164],3.71667,51.05,{"lat":164,"lon":163},{"facility":167,"status":140,"city":168,"state":11,"zip":169,"country":151,"countryCode":152,"cosmosGeoPoint":170,"geoPoint":174,"contacts":11},"UZ Leuven","Leuven","3000",{"type":133,"coordinates":171},[172,173],4.70093,50.87959,{"lat":173,"lon":172},{"facility":176,"status":140,"city":177,"state":11,"zip":11,"country":178,"countryCode":179,"cosmosGeoPoint":180,"geoPoint":184,"contacts":11},"Universitaetsklinikum Heidelberg","Heidelberg","Germany","DE",{"type":133,"coordinates":181},[182,183],8.69079,49.40768,{"lat":183,"lon":182},{"facility":186,"status":140,"city":187,"state":11,"zip":11,"country":188,"countryCode":189,"cosmosGeoPoint":190,"geoPoint":194,"contacts":11},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","Roma","Italy","IT",{"type":133,"coordinates":191},[192,193],11.10642,44.99364,{"lat":193,"lon":192},{"facility":196,"status":140,"city":197,"state":11,"zip":198,"country":188,"countryCode":189,"cosmosGeoPoint":199,"geoPoint":203,"contacts":11},"nstituto Clinico Humanitas","Rozzano","20089",{"type":133,"coordinates":200},[201,202],9.1559,45.38193,{"lat":202,"lon":201},{"facility":205,"status":140,"city":206,"state":11,"zip":11,"country":207,"countryCode":208,"cosmosGeoPoint":209,"geoPoint":213,"contacts":11},"Antoni van Leeuwenhoek","Amsterdam","Netherlands","NL",{"type":133,"coordinates":210},[211,212],4.88969,52.37403,{"lat":212,"lon":211},{"facility":215,"status":140,"city":216,"state":11,"zip":11,"country":217,"countryCode":218,"cosmosGeoPoint":219,"geoPoint":223,"contacts":11},"Hospital HM Nou Delfos","Barcelona","Spain","ES",{"type":133,"coordinates":220},[221,222],2.15899,41.38879,{"lat":222,"lon":221},{"facility":225,"status":140,"city":216,"state":11,"zip":11,"country":217,"countryCode":218,"cosmosGeoPoint":226,"geoPoint":228,"contacts":11},"VHIO, Vall d'Hebron University Hospital",{"type":133,"coordinates":227},[221,222],{"lat":222,"lon":221},{"facility":230,"status":140,"city":231,"state":11,"zip":11,"country":217,"countryCode":218,"cosmosGeoPoint":232,"geoPoint":236,"contacts":11},"Centro Integral Oncologico Clara Campal","Madrid",{"type":133,"coordinates":233},[234,235],-3.70256,40.4165,{"lat":235,"lon":234},{"facility":238,"status":140,"city":231,"state":11,"zip":11,"country":217,"countryCode":218,"cosmosGeoPoint":239,"geoPoint":241,"contacts":11},"Hospital Universitario Fundacion Jimenez Diaz",{"type":133,"coordinates":240},[234,235],{"lat":235,"lon":234},{"type":243,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100580655",false,"NCT06840119","Phase 1\u002F2 Study of IMC-R117C in Selected Advanced Cancers","A Phase 1\u002F2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* HLA-A\\*02:01-positive\n* Histologically confirmed advanced colorectal, esophageal, gastric, or ovarian carcinoma\n* Archived or fresh tumor tissue sample that must be confirmed as adequate\n* Evaluable\u002FMeasurable disease per RECIST 1.1\n* Previously received applicable standard treatments\n* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control\n\nExclusion Criteria:\n\n* Symptomatic or untreated central nervous system metastasis\n* Recent bowel obstruction\n* Ongoing ascites or effusion requiring recent drainages\n* Significant ongoing toxicity from prior anticancer treatment\n* Out-of-range laboratory values\n* Clinically significant lung, heart, or autoimmune disease\n* Ongoing requirement for immunosuppressive treatment\n* Significant secondary malignancy\n* Hypersensitivity to study drug or excipients\n* Pregnant or lactating","ALL","18 Years",{"count":253,"type":254},600,"ESTIMATED","INTERVENTIONAL",[257,258],"PHASE1","PHASE2","This phase 1\u002F2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.",[261,262],"Cancer","HLA-A*02:01-positive","2026-01-26",{"date":265,"type":266},"2026-01-28","ACTUAL",{"date":268,"type":266},"2024-01-10",{"date":270,"type":254},"2027-11-30",{"name":5,"class":6},13]